Avalo Therapeutics Inc
(AVTX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Sales | 441 | 1,924 | 18,051 | 5,398 | 6,699 |
| Cost of Goods | -366 | 1,284 | 3,434 | 1,491 | 300 |
| Gross Profit | 807 | 640 | 14,617 | 3,907 | 6,399 |
| Operating Expenses | 68,953 | 28,275 | 52,491 | 86,532 | 79,542 |
| Operating Income | -68,512 | -27,351 | -37,440 | -82,134 | -72,843 |
| Interest Expense | 0 | 0 | 4,170 | 2,391 | 0 |
| Other Income | 33,497 | -4,179 | -20 | -20 | 5,666 |
| Pre-tax Income | -35,015 | -31,530 | -41,630 | -84,545 | -67,177 |
| Income Tax | 114 | 14 | 28 | -196 | -2,793 |
| Net Income Continuous | -35,129 | -31,544 | -41,658 | -84,349 | -64,384 |
| Net Income Discontinuous | N/A | N/A | N/A | -27 | 884 |
| Net Income | $-35,129 | $-31,544 | $-41,658 | $-84,376 | $-63,500 |
| EPS Basic Total Ops | -7.94 | -113.58 | -1,063.00 | -2,369.05 | -2,458.13 |
| EPS Basic Continuous Ops | -7.94 | -113.58 | -1,062.65 | -2,369.05 | -2,486.71 |
| EPS Basic Discontinuous Ops | N/A | N/A | N/A | -0.77 | 28.58 |
| EPS Diluted Total Ops | -20.91 | -113.58 | -1,063.00 | -2,369.05 | -12,347.80 |
| EPS Diluted Continuous Ops | -4.69 | -113.58 | -1,062.65 | -2,369.05 | -12,519.29 |
| EPS Diluted Discontinuous Ops | N/A | N/A | N/A | -0.77 | 171.50 |
| EPS Diluted Before Non-Recurring Items | -20.91 | -114.00 | -1,054.76 | -2,372.38 | -1,629.22 |
| EBITDA(a) | $-68,343 | $-21,458 | $-35,885 | $-79,683 | $-71,000 |